Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (now known as AZD1222).
SeraNovo B.V. today announced that it has signed a second License Agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors.
The Korean biotech company Macrogen (CEO Sukang Lee), announced that it obtained export approval for COVID-19 test kit 'AxenTM COVID-19 RT' from the Ministry of Food and Drug Safety (MFDS) on the 18th.
Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces SoteriaRx™.
Zymo Research announced that the US Food and Drug Administration (FDA) has approved its Quick SARS-CoV-2 rRT-PCR Kit (R3011) for Emergency Use Authorization (EUA) for the detection of SARS-CoV-2, the virus that causes COVID-19.
Technopath Clinical Diagnostics today launched its Multichem ID-COVID-19 Quality Control Solutions offering laboratories third-party quality control products enabling an independent, totally unbiased assessment of a diagnostic device or method for COVID-19 antibody testing.
Alume Biosciences, Inc., a biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that it has received a "Study May Proceed" letter from the US Food and Drug Administration (FDA) related to its recently filed Investigational New Drug (IND) application for the use of ALM-488 in head and neck surgery.
Yiling Pharmaceutical announced that Yiling Pharmaceutical and its subsidiary Beijing Yiling Pharmaceutical had received the approval document of drug supplement application concerning the application for new indications of Lianhua Qingwen capsules and Lianhua Qingwen granules issued by State Drug Administration.
The Feinstein Institutes for Medical Research, the research arm of Northwell Health, announced today it has formally joined a national network formed by Mayo Clinic to collect convalescent plasma from patients previously identified with COVID-19, but no longer symptomatic.
BlueWillow Biologics®, a clinical-stage biopharmaceutical company, today announced the company will advance the manufacturing and commercialization of NanoBio® Protect, a nasal antiseptic solution that can be used to help reduce germs that could cause infections.